Lifeline Begins Human Testing of Protandim CF

[Guest guest]

LIFELINE NUTRACEUTICALS, INC.Contact: Bill Driscoll, President/CEOinfo@...http://www.lifelinenutraceuticals.com

FOR IMMEDIATE RELEASE

Lifeline Begins Human Testing of Protandim CF

Denver Nutraceuticals Company starts testing at the Webb-Waring Institute for Cancer, Aging and Antioxidant Research

DENVER, CO, OCT. 20, 2004. Lifeline Nutraceuticals, Inc. (Lifeline) has begun human trials of its much-anticipated antioxidant therapy, Protandim CF. Once again, scientists at the world-renowned Webb-Waring Institute for Cancer, Aging and Antioxidant Research (Webb-Waring) will be conducting the studies.

The purpose of the studies are to observe and record the effects of Protandim CF on the levels of activity of the antioxidant enzymes, Superoxide Dismutase (SOD), Catalase (CAT) and Glutathione Peroxidase (GPX) in blood cells, and on plasma malondialdehyde and lipid peroxide levels. The Webb-Waring scientists will examine young healthy adults, aged but otherwise healthy adults, and those with chronic diseases such as diabetes. Diabetes is one common disease that shows evidence of chronic oxidative stress as measured by increased lipid peroxidation.

While it has been thought that the antioxidant vitamins C and E, as well as many other antioxidants found in fresh fruits and vegetables, serve to limit lipid peroxidation in vivo, recent studies have shown that supplemental vitamins C and E produced no effect on biomarkers of lipid peroxidation on healthy men with low fruit and vegetable intake (whether smokers or non-smokers). Lifeline believes that Protandim CF offers a better approach - to upregulate the family of antioxidant enzymes. Lifeline's recent pre-clinical studies (also conducted at Webb-Waring) produced significant results, with lipid peroxidation being reduced by more than 90% in the brains of mice. Although not guaranteed, Lifeline fully expects the human trials to show similar results.

Methods:

Webb-Waring will isolate red cells and plasma from blood drawn from participating individuals at the beginning of the study. The cells will be analyzed for SOD, CAT and GPX activity levels. Plasma will be analyzed for lipid peroxidation products (TBARS, FOX assay), cholesterol, triglycerides, C-reactive protein and uric acid.

Subjects in the preliminary dose-response study will then be given a 30-day supply of capsules. After 30 days, the subjects will return for a second blood draw and analysis identical to the first and will then be given an additional 90-day supply of capsules. These analyses will be compared, and all changes in the parameters recorded and analyzed. Thus, each individual will serve as his/her own control. There will be no control or placebo treated groups. Finally, after 120 days, the supplement treatment will be terminated and subjects will return for a third and final blood draw and analysis.

In these studies, Lifeline hopes to see not only elevated activities of the antioxidant enzymes, but also significant decreases in markers of oxidative stress, especially in the elderly and in those with chronic diseases such as diabetes.

Recruiting:

For this pilot study, Webb-Waring is recruiting participants from the community at large in the Denver area. A web page has been created to describe the study and to invite participants. The Webb-Waring Institute has a web presence (http://www.webb-waring.org) visited by substantial numbers of people with an interest in aging and diseases of oxidative stress. Any mentally competent adult (over 18) may participate in the study. The important variables known to affect lipid peroxidation are age and disease status; accordingly, the study's subgroups are selected to reflect these differences.

ABOUT WEBB-WARING INSTITUTE FOR CANCER, AGING AND ANTIOXIDANT RESEARCH…

Information about the Webb-Waring Institute for Cancer, Aging and Antioxidant Research can be found at: http://www.webb-waring.org

ABOUT LIFELINE NUTRACEUTICALS CORP…

Lifeline is a privately held, Denver-based company formed to manufacture, market and distribute nutraceutical supplements that promote "Healthy Life Expectancy." Lifeline is focusing exclusively on unique antioxidant therapies under its Protandim brand. The therapies center on the body's primary defense mechanism against oxidative stress - the natural antioxidant enzymes, Superoxide Dismutase (SOD), Catalase (CAT), and Glutathione Peroxidase (GPX). Discussions have commenced regarding license agreements and other collaborative arrangements in order to aggressively place its Protandim product candidates into the global marketplace.

For more information, please contact Bill Driscoll at info@...

The latest news updates are available at http://www.lifelinenutraceuticals.com/newsroom.html

This news update contains forward-looking statements regarding the testing and commercialization of Lifeline's products. Such statements involve risks and uncertainties that could cause future actual results to differ due to a variety of risk factors. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by Lifeline's management; changes in the regulatory process; changes in market trends; and a number of other factors. Lifeline does not undertake and specifically declines any obligation to update, republish or revise forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrences of unanticipated events.

"###"